New research suggests that people who stop using popular slimming jabs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who end conventional diet and exercise programs.
Published data in a prominent health publication shows that while obese people frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing these drugs should be cognizant of the risk of rapid rebound weight gain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment mass within about 18 months.
Weighing Approaches
The research, which reviewed 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.
Scientists point out that people who lose weight through dieting usually have a more gradual weight regain—approximately 100 grams monthly—after stopping.
Explaining the Quick Rebound
Experts propose the mode of action of the drugs explains the accelerated regain.
The injections mimic a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to appetite is unsuppressed, making excessive eating far more likely."
A Chronic Issue?
Medical guidelines suggest the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Many experts say that, given the high risk of weight regain, the treatment might need to be life-long.
This opinion is reinforced by drug manufacturers, who state that the results "highlight the long-term character of excess weight," akin to managing diseases like diabetes.
User Testimonies
Individuals who have come off the jabs explain a powerful resurgence of cravings.
"I experienced a switch that goes on and I was suddenly starving," said an individual.
This challenge is exacerbated if users have not developed sustainable lifestyle or habit changes during treatment.
Widespread Interest
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Adoption is greater among women compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone solution and lasting health benefits relies on ongoing behavioural support.
